D4 Labs, LLC announced that it has received a U.S. Patent #11911461 for its subcutaneously administered adjuvant, SubATVax™, using modified sequences of the SARS-CoV-2 (COVID-19) S1 sequence. A paper describing the preclinical testing of this technology, when administered subcutaneously, was published in bioRxiv in September 2023.
Dr. Wright, the Chief Scientific Officer at D4 Labs, LLC said the following:
“We have spent the last four years developing SubATVax™ technology. Our hypothesis was that we could develop refrigerated, adjuvanted vaccines, which could be administered subcutaneously in a small volume (300 μL) in a one-or two-dose format. The aforementioned patent and paper describe this work in detail. Additionally, we successfully completed a two-year stability study on this refrigerated, adjuvanted SARS-CoV-2 vaccine. We would encourage other companies, government laboratories, and academic centers to contact us about utilizing our technology with either approved vaccines or new vaccines in development.”
For more information, please contact Dr. Wright (831) 664-5464